Table 3.
Chemotherapy and intrathecal treatment at relapse
| Chemotherapy drugs | Number of patients | ||
|---|---|---|---|
| All patients | Isolated PF-relapses | Metastatic relapses | |
| Temozolomide | 24 | 2 | 22 |
| Carboplatin + etoposide ± cyclophosphamide | 15 | 3 | 12 |
| Cyclophosphamide | 5 | 0 | 5 |
| Trophosphamide + etoposide | 3 | 0 | 3 |
| Temozolomide + irinotecan | 4 | 2 | 2 |
| Gemcitabine + oxaliplatin | 2 | 0 | 2 |
| Other combinations | 3 | 1 | 2 |
| Drugs not specified | 5 | 3 | 2 |
| No chemotherapy | 7 | 1 | 6 |
| No data | 4 | 1 | 3 |
| Intrathecal chemotherapy drugs | 17 | ||
| Etoposide | 7 | ||
| Methotrexate | 6 | ||
| Cytarabine | 3 | ||
| Other | 1 | ||
| No intrathecal chemotherapy | 49 | ||
| No data | 6 | ||